{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T01:05:16Z","timestamp":1760403916359,"version":"build-2065373602"},"reference-count":30,"publisher":"Wiley","issue":"3-4","license":[{"start":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T00:00:00Z","timestamp":1453766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:p>This paper reports a typical statin\u2010related adverse reaction from a red yeast rice (RYR) supplement and the analytical findings from the supplement. It also examines the regulatory framework governing botanical supplements in Europe. Two key events that shaped the current regulatory framework are reviewed. First, the Hecht\u2010Pharma judgement by the European Court of Justice (ECJ) that inverted the precautionary principle in the Medicines Act to a reactionary principle. Following the Hecht\u2010Pharma judgement, pharmacological active dietary supplements can be sold until sufficient signals of harm show that they are an unregistered medicine, placing a huge burden on regulatory authorities. Secondly, the European Food Safety Authority (EFSA) in 2011 approved the first health claim for pharmacologically active RYR dietary supplements. If the current regulatory status for pharmacologically active RYR dietary supplements does not permit adequate warning and active monitoring of adverse drug reactions, then the current regulatory framework may not be adequate to ensure consumer safety.Copyright \u00a9 2016 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/dta.1929","type":"journal-article","created":{"date-parts":[[2016,1,26]],"date-time":"2016-01-26T02:52:44Z","timestamp":1453776764000},"page":"315-318","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacologically effective red yeast rice preparations marketed as dietary supplements illustrated by a case report"],"prefix":"10.1002","volume":"8","author":[{"given":"B.J.","family":"Venhuis","sequence":"first","affiliation":[{"name":"National Institute for Public Health and the Environment <i>RIVM<\/i>  A. van Leeuwenhoeklaan 9 3721MA Bilthoven The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"van Hunsel","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre <i>Lareb<\/i>  Goudsbloemvallei 9 5237 MH 's\u2010Hertogenbosch The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"van de Koppel","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre <i>Lareb<\/i>  Goudsbloemvallei 9 5237 MH 's\u2010Hertogenbosch The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.H.J.","family":"Keizers","sequence":"additional","affiliation":[{"name":"National Institute for Public Health and the Environment <i>RIVM<\/i>  A. van Leeuwenhoeklaan 9 3721MA Bilthoven The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.M.F.","family":"Jeurissen","sequence":"additional","affiliation":[{"name":"National Institute for Public Health and the Environment <i>RIVM<\/i>  A. van Leeuwenhoeklaan 9 3721MA Bilthoven The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"De Kaste","sequence":"additional","affiliation":[{"name":"National Institute for Public Health and the Environment <i>RIVM<\/i>  A. van Leeuwenhoeklaan 9 3721MA Bilthoven The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,26]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"EUR\u2010lex.Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Available at:http:\/\/eur\u2010lex.europa.eu\/legal\u2010content\/EN\/TXT\/HTML\/?uri=CELEX:32001L0083&rid=2[7 September 2015]."},{"key":"e_1_2_6_3_1","unstructured":"European Court of Justice.C\u2010140\/07 \u2010 Hecht\u2010PharmaAvailable at:http:\/\/curia.europa.eu\/juris\/liste.jsf?language=en&num=C\u2010140\/07[7 September 2009]."},{"key":"e_1_2_6_4_1","first-page":"93","article-title":"Scientific Opinion on the Regulatory Status of 1,3\u2010Dimethylamylamine (DMAA)","volume":"2","author":"Venhuis B. J.","year":"2012","journal-title":"Eur. J. Food Res. Rev."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.854"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.200690011"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2004.04.004"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2014.07.039"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1987.tb03524.x"},{"key":"e_1_2_6_10_1","unstructured":"Merck.Patient information leaflet for Mevacor tablets. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/019643s088lbl.pdf[24 April 2015]."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2000.00106.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363070-00007"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.111.000071"},{"key":"e_1_2_6_14_1","unstructured":"A.DePalma.Pharma marketing and sales: When to make an Rx to OTC switch. Available at:http:\/\/social.eyeforpharma.com\/commercial\/pharma\u2010marketing\u2010and\u2010sales\u2010when\u2010make\u2010rx\u2010otc\u2010switch[24 April 2015]."},{"key":"e_1_2_6_15_1","first-page":"151","article-title":"Latebreakers: If Mevacor goes OTC, Glaxo will push it","volume":"23","year":"2007","journal-title":"Drug Topics"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.07.051"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2012.09.003"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2005.11.1031"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-12-200906160-00006"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200210270-00028"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.02.021"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.382"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-015-0495-8"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.04.004"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.2903\/j.efsa.2011.2304"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1315559"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.109.203596"},{"key":"e_1_2_6_28_1","unstructured":"T.U.M. Centre.The use of the WHO\u2010UMC system for standardised case causality assessment. Available at:http:\/\/www.who\u2010umc.org\/Graphics\/26649.pdf[7 October 2015]."},{"key":"e_1_2_6_29_1","unstructured":"B.J.Venhuis D.D.Kaste.Unpublished results for study PC2010\u2010016.2011."},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-012-0357-x"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.2903\/j.efsa.2013.3327"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.1929","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdta.1929","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.1929","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dta.1929","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.1929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T21:21:31Z","timestamp":1760390491000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.1929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,26]]},"references-count":30,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1002\/dta.1929"],"URL":"https:\/\/doi.org\/10.1002\/dta.1929","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"type":"print","value":"1942-7603"},{"type":"electronic","value":"1942-7611"}],"subject":[],"published":{"date-parts":[[2016,1,26]]}}}